Search

Displaying results 7371 - 7380 of 10000 in total
  1. Drug

    Ningetinib

    go.drugbank.com/drugs/DB16256
    Investigational

    Ningetinib is under investigation in clinical trial NCT03758287 (Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).

  2. Drug

    Avizakimab

    go.drugbank.com/drugs/DB18842
    Investigational

    Avizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).

  3. Drug

    LY-2624803

    go.drugbank.com/drugs/DB15092
    Investigational

    LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).

  4. Drug

    Dinoprost

    go.drugbank.com/drugs/DB12789
    ApprovedWithdrawn

    Dinoprost has been investigated in Headache.

  5. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    )[L12675] with an expected completion in December 2020. … [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906

  6. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).

  7. Drug

    Refanezumab

    go.drugbank.com/drugs/DB14908
    Investigational

    Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).

  8. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].

  9. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    Furvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.

  10. Drug

    Sitravatinib

    go.drugbank.com/drugs/DB15036
    Investigational

    Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).